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A reduction in salt intake reduces blood pressure, stroke and other cardiovascular events, 34 
including chronic kidney disease, by as much as 23% (i.e. 1.25M deaths worldwide). It is 35 
effective in both genders, any age, ethnic group, high, medium and low-income 36 
countries. Population salt reduction programmes are both feasible and effective 37 
(preventive imperative). Salt reduction programmess are cost-saving in all settings (high-, 38 
middle- and low-income countries) (economic imperative). Public health policies are 39 
powerful, rapid, equitable, cost-saving (political imperative). The important shift in the 40 
public health has not occurred without obstinate opposition from organizations 41 
concerned primarily with the profits deriving from population high salt intake and less 42 
with public health benefits. Key components of the denial strategy are misinformation 43 
(with ‘‘pseudo’’ controversies). In general, poor science has been used to create 44 
uncertainty and to support inaction. This paper summarises the evidence in favour of a 45 
global salt reduction strategy and analyses the peddling of well-worn myths behind the 46 
false controversies. 47 
 48 
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Since 1985 the World Health Organization (WHO) has been recommending a reduction in 51 
population salt intake to an average of 5g per day from a country customary 52 
consumption. However, no action plan was ever put in place globally, although 53 
noticeable implementations in Japan1 and Finland2 led to dramatic reductions in 54 
cardiovascular disease (CVD) and stroke rates associated with substantial reductions in 55 
population salt intake. Over the following 20 years both scientific evidence and public 56 
health initiatives have led to renewed recommendations from the WHO in 20073 and 57 
20124 not to exceed a population average salt intake of 5g per day. A significant step 58 
toward global policy action was the 2011 United Nations high-level meeting on non-59 
communicable diseases (NCDs), which set a target for population salt reduction as a 60 
priority to reduce premature CVD mortality by 20255. Revised WHO guidelines now 61 
recommend a 30% reduction of salt intake by 2025 and a final maximum target of 5g per 62 
day4. The latter target was then adopted by the 66th World Health Assembly through its 63 
resolution in 20136. A number of policy options for the implementation of national 64 
programmes globally are now available7 and population salt reduction is underway in 65 
many countries worldwide8. 66 
 67 
“Salt debate” 68 
In parallel with these actions, a ‘salt debate’ has filled the pages of health magazines and 69 
newspapers for years. From John Swales’ original scepticism in 1988
9
 to the Godlee’s 70 
sharp call to reality in 1996
10
, the debate has transcended the scientific arena into public 71 
opinion and media campaigns with increasingly passionate tones
11
. The controversy has 72 
been particularly heated since the translation of the results of scientific studies into 73 
public health and policy actions
7
 and the ‘salt debate’ has become for some a ‘salt war’
12
. 74 
The progression of this debate into a war resembles past and present debates (let us 75 
think at John Snow and the cholera epidemic of the 19
th
 century, the long-lasting denial 76 
of the harm of tobacco smoking of the 20
th
 century, the global warming and climate 77 
change debate of the 21
st
 century), when the translation of science into practice clashes 78 
with vested interests
12-14
.  79 
 80 
 81 


































































The evidence 83 
 84 
Salt and blood pressure 85 
The scientific facts are: salt is causally related to blood pressure (BP), the higher the salt 86 
intake, the higher the BP, an effect seen since birth14. A small and sustained reduction in 87 
salt intake (up to 50% of what we eat now) causes a fall in BP in almost everyone across 88 
the whole range of BP, although individuals will respond more or less, depending on 89 
factors like age, ethnicity, initial levels of BP, body weight. These facts have been proven 90 
over and over again and summarised in repeated systematic reviews and meta-analyses 91 
of small and large clinical trials in people with and without high BP.  92 
 93 
[INSERT FIGURE HERE) 94 
 95 
The Figure shows the collective estimates of all meta-analyses published to date on the 96 
effect of salt reduction on BP in adults15-25. The meta-analyses differ for the time of the 97 
analysis, hence the number of overall studies available, the inclusion criteria (short-term 98 
studies of less than 4 weeks versus longer-term studies of more than 4 weeks), the 99 
proportion of normotensive and hypertensive participants, the study designs (cross-over, 100 
parallel group, blinded, and unblinded), and the proportion of relevant subgroups (by 101 
gender, age, and ethnic group). Despite differences between studies, the range of pooled 102 
weighted estimates of effect are all in favour of salt reduction. Furthermore their 95% 103 
confidence intervals are compatible with each other, indicating consistency, with 104 
differences between them likely due to random variation. Furthermore, when using very 105 
‘short-term salt restriction’ trials with very large changes in salt intake (unlikely to be 106 
comparable to ‘longer-term more moderate salt reduction’ ones) it has been argued that 107 
changes in metabolic and hormone variables may occur
17, 20-23
. These changes are due to 108 
rapid and transient activation of sympathetic adrenergic activity and 109 




.  In conclusion, the results of these analyses, despite different interpretations at the 111 
time of their publication, all agree on the following: (1) salt intake is one of the major 112 
determinants of BP in populations and individuals; (2) a reduction in salt intake causes a 113 

































































dose-dependent reduction in BP; and (3) the effect is seen in both sexes, in people of all 114 
ages and ethnic groups, and with all starting BPs. Similar results have been described in 115 
children26-27. 116 
 117 
Salt and cardiovascular outcomes 118 
High BP contributes to strokes and heart attacks and a reduction in blood pressure is 119 
associated with their reduction. The effect is related to the size of the fall in BP. It is 120 
therefore conceivable that a moderate reduction in salt intake in a population would help 121 
reduce stroke and heart attacks through a reduction in BP. The collective evidence from 122 
systematic reviews of prospective longitudinal studies indicates that a lower salt intake is 123 
associated with a lower incidence of fatal and non-fatal cardiovascular events, in 124 
particular stroke25,28. This is supported by a meta-analysis of the few randomised clinical 125 
trials available to date which have measured fatal and non-fatal outcomes29. However, to 126 
prove that a reduction of salt intake in populations over an extended period of time 127 
reduces the rate of strokes and heart attacks a randomized double-blind placebo-128 
controlled clinical trial would be needed. It has been argued that such a ‘mother of trials’ 129 
will never be conducted but, nevertheless, we should not refrain from implementing 130 
public health policies based on the available evidence so far30. Never was a randomized 131 
clinical trial of tobacco smoking and lung cancer carried out in humans to ‘prove’ that 132 
smoking causes lung cancer and that we should eventually ban tobacco. Furthermore, an 133 
assessment of the bulk of evidence underlying population action of salt reduction dwarfs 134 
the evidence that today supports accepted policies on weight reduction, physical 135 
inactivity, dietary intake of fibre, fruit and vegetable for the prevention of both cancer 136 
and CVD. A recent controversy has been fuelled by a series of reports of analyses of 137 
prospective observational studies suggesting that lower salt intake might be associated 138 
with increased risk of CVD events, in particular coronary events and heart failure. These 139 
studies have been the object of intense scrutiny due to numerous methodological issues 140 
present in observational studies that would introduce fatal biases (errors) in the results 141 
and, hence, erroneous conclusions. A comprehensive account on these issues has been 142 
published by the American Heart Association
31
.  143 
 144 
[INSERT TABLE HERE] 145 


































































The Table provides a simple schematic summary of these methodological issues 147 
determining contrasting results. In brief, the risk of errors pertains the domains of 148 
systematic errors in the assessment of salt intake, the presence of ‘reverse causality’ 149 
bias, the presence of residual confounding, random errors and insufficient statistical 150 
power. Moreover, prospective observational studies do not imply true ‘cause-effect’ 151 
relationship, and they must be interpreted in the context of other available evidence32, 152 




Albeit applying different methods and models of assessment in different health care 157 
systems and under different assumptions, several studies have invariably demonstrated 158 
that a reduction in salt intake is cost-saving for the health care system (see14 for review). 159 
In the United States, a salt reduction of 3g per day would result in an estimated annual 160 
gain of 194,000 to 392,000 QALYs and estimated savings of $10 billion to $24 billion (US) 161 
in health care costs. That represents $6 to $12 (US) return on investment for each dollar 162 
spent on the regulatory program33. Even a more modest reduction of 1g per day achieved 163 
gradually over 10 years would be more cost-effective than using medications to lower BP 164 
in all patients with hypertension
34
. These economic savings would be achieved with 165 
either voluntary or mandatory reductions in the salt content of processed foods. 166 
However, health benefits would be up to 20 times greater with government legislation 167 
on salt limits in processed foods
35
. Cost savings are also estimated for a 15% reduction in 168 
salt intake in low- and middle-income countries, which would avert 13.8 million deaths 169 
over 10 years at an initial cost of less than $0.40 (US) per person per year. In conclusion, 170 
population salt reduction is an effective and cost-saving public health measure.  171 
 172 
The myths 173 
The important shift in the public health debate from ‘whether’ salt reduces the risk to 174 
‘how’ to best lower salt intake to reduce CVD has not occurred without obstinate 175 
opposition from organizations concerned primarily with the profits deriving from 176 
population high salt intake and less with public health benefits. The food and beverage 177 

































































industry has been particularly obstructive regarding public health actions, either directly 178 
or through its public relations organizations. Its strategies have included mass media 179 
campaigns, biasing research findings, co-opting policy makers and health professionals, 180 
lobbying politicians and public officials, encouraging voters to oppose public health 181 
regulation12,36-37. Key components of this denial strategy are misinformation (with 182 
‘‘pseudo’’ controversies)38 and the peddling of numerous rather well-worn myths13. In 183 
general, poor science has been used to create uncertainty and to support inaction. Clear 184 
examples are given by recent debates generated by publications using flawed 185 
methodologies39 (see Table) and subsequently retracted data40 robustly rebutted by the 186 
scientific community but sadly still used to support the controversy41-43. In particular, the 187 
claim that low salt intake may ‘cause’ coronary death has been proven not to be true, as 188 
shown by US, Dutch, and global studies using valid and appropriate methods44. Finally, 189 
reiterated myths have been disseminated to consumers and lay audience to create 190 
doubts13-14.  191 
 192 
Who gains from the controversy? 193 
Why is the food and beverage industry so opposed to an approximate one third global 194 
reduction in salt intake? Salt is a cheap commodity everywhere. In 2009, more than 27 195 
million tons of salt were sold in the United States for a revenue of US$2 billion; only 1.5 196 
million tons of food-grade salt fetched more than US$320 million. Notwithstanding these 197 
figures, the use of salt in food manufacturing generates substantial profits for the food 198 
and beverage industry. The world’s 10 largest food and non-alcoholic beverage 199 
companies—feeding an estimated global population of several hundred million in more 200 
than 200 countries daily — generated a combined annual revenue of more than US$422 201 
billion in 2012. A high salt intake contributes to the profit through several mechanisms: 202 
(i) it will generate a demand for salty foods through a slow process of desensitization of 203 
the taste buds; (ii) since sodium salts are hygroscopic, absorbing and binding water, the 204 
practice of injecting meat products with sodium salt bound to stabilizers increases the 205 
weight of meat products before packaging so that the water trapped in the meat is sold 206 
at the price of meat; (iii) salt makes cheap, unpalatable food edible at no extra cost; (iv) it 207 
causes thirst and an increase in the use of mineral waters, soft drinks and often alcoholic 208 
beverages. The high use of sugar-containing drinks would contribute to the epidemic of 209 

































































obesity, particularly in children, and high salt intake might encourage an increase in 210 
alcohol intake. A reduction in salt intake as recommended by the WHO would result in an 211 
average reduction in fluid consumption of approximately 350 mL per day per person45. In 212 
children, this would also lead to a reduction of at least 2.3 sugar-sweetened soft drinks 213 
per week per child46. Although this would result in large beneficial effects to the health of 214 
the population and financial gains for governments, it would be a multibillion-dollar loss 215 
to the industry from reduced sales of bottled water, soft drinks and alcoholic beverages. 216 
 217 
Conclusions 218 
A reduction in salt intake reduces BP, stroke and other cardiovascular events by as much 219 
as 23% (i.e. 1.25M deaths worldwide). It is effective in both genders, any age, ethnic 220 
group, high, medium and low-income countries. Population salt reduction programmes 221 
are both feasible and effective (preventive imperative). Salt reduction programmess are 222 
cost-saving in all settings (high-, middle- and low-income countries) (economic 223 
imperative). Public health policies are powerful, rapid, equitable, cost-saving (political 224 
imperative).  225 
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Figure. Forest-plot summarising the results of published meta-analyses of randomized 353 
clinical trials of the effects of salt reduction on systolic blood pressure. Results are reported 354 
as SMD and 95% C.I.s. (re-drawn from Reference 14) 355 
 356 
Table. Methodological issues in the assessment of prospective observational studies of salt 357 
consumption and cardiovascular outcomes (re-drawn from Reference 31) Reference list in 358 
Appendix 1. 359 




























































































































Table. Methodological issues in the assessment of prospective observational studies of salt consumption and cardiovascular outcomes. 
Domain 1 Errors with the greatest potential to alter the direction of association (with examples) 
 
Systematic error in sodium assessment 
• Lower risk: 24h urine collections not part of routine clinical practice, no quality assurance, not excluding 
incomplete collections. 
• Higher risk: other 24h urine collections, all dietary assessments, spot and overnight urine collections. 
Dong 2010; Stolarz-Skrzypek 2011; 
Alderman 1995; 1998; Cohen 2006; 
2008; Gardener 2012; Arcand 2011 
Reverse causality 
• Lower risk: participants recruited from general population and pre-existing CVD excluded 
• Intermediate risk: sick populations not excluded or included despite stated otherwise; presence of CVD risk 
factors; specific sick populations  
• Higher risk: specific sick populations (eg: heart failure, kidney disease, diabetes); removal of sick 
participants from analysis changes direction of association 
Dong 2010; Arcand 2011; Son 
2011; McCausland 2012; Gardener 
2012; O’Donnell 2011; Thomas 
2011; Ekinci 2011; Lennie 2011 
Domain 2 Errors with some potential to alter the direction of association (with examples) 
 
Potential for residual confounding 
• Incomplete adjustment: not including 2 or more of ag , sex, race, SES, cholesterol, BMI or weight, smoking, 
diabetes; if diet-based, total calories; in urine-based weight, BMI or creatinine excretion 
• Imbalance across sodium intake levels: age difference across sodium groups >5 years; sex or race 
distribution across sodium groups >20% 
• Inadequate follow-up: low level of follow-up (<80%) or of uncertain quality for outcome assessment 
Alderman 1995; 1998; Takachi 
2010; Tunstall-Pedoe 1997; 
Tuomilehto 2001; Stolarz-Skrzypek 
2011; Dong 2010; Arcand 2011; 
McCausland 2012; Son 2011; 
Thomas 2011; Ekinci 2011; Nagata 
2004; Umesawa 2008; Cook 2009 
Domain 3 Errors with the potential to lead to a false null result (with examples) 
 
Random error in sodium assessment 
• Lower risk: more than four 24h urine assessments on average; FFQs 
• Intermediate risk: between 22-4 24h urine collections, or corrections for regression dilution bias; dietary 
reports 
• Higher risk: urine collection <24h or single 24h urine collection; single dietary recall or 1-dat food record 
Insufficient power 
• Less than 80% power to detect a 10% reduction in relative risk for every standard deviation in sodium 
intake 
Nagata 2004; Tuomilehto 2001; 
Cook 2009; Dong 2010; Arcand 
2011; Alderman 1995; Son 2011; 
Ekinci 2011; Yang 2011 
 Studies using same data with divergent results 
 
• NHANES I studies: same age group, same follow-up – inverse vs positive association 
• NHANES III studies: different age groups, different follow-up – inverse vs positive association 
Alderman 1998; He 1999  
Cohen 2008; Yang 2011 
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